All In Biotech

Drug Trial Radar · NCT05092386

Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

An Open-label Combined Randomized Double-blind, Positive Control Clinical Trial in Subjects Aged 2 Months (Minimum 6 Weeks) and Above to Preliminary Evaluate the Safety and Immunogenicity of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 310 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

310

Actual

Start

Jan 3, 2023

Primary completion

May 26, 2024

Study completion May 28, 2024

Sponsor

Sponsor type
Industry
First posted
Oct 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 weeks, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is an open-label combined randomized double-blind, positive control phase Ⅰ clinical trial of the a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine manufactured by Sinovac Research \& Development Co., Ltd. The purpose of this study is to preliminary evaluate the safety and immunogenicity of the study vaccine

Conditions

  • Pneumococcal Infections

Interventions

  • Investigational 13-valent Pneumococcal Polysaccharide Conjugate VaccineBiological

    The investigational vaccine was manufactured by Sinovac Research \& Development Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and diphtheria CRM197 in 0·5 mL of aluminum phosphate ,sodium chloride,polysorbate 80 and succinic acid per injection.

  • Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13)Biological

    The control vaccine was manufactured by WALVAX Biotechnology Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,disodium hydrogen phosphate and sodium dihydrogen phosphate per injection.

  • Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( Pfizer PCV13)Biological

    The control vaccine was manufactured by Pfizer. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,sodium chloride ,succinic acid ,polysorbate 80 and water for injection per injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety index-incidence of adverse reactionsTime frame: Day 0-30 after each dose of experimental vaccine

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan Center for Diseases Control and Prevention

    Zhengzhou, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.